| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,032 | 0,033 | 17:01 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Biovica International: New phase III Translational Data Show DiviTum TKa Captures Treatment-Specific Biological Response in Metastatic Breast Cancer | 301 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / May 28, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, specializing in blood-based cancer monitoring, today announced new data published... ► Artikel lesen | |
| 26.05. | Biovica International: Biovica Receives Expanded Work Order from Clinical-Stage Oncology Company for Next-Generation CDK Inhibitor Program | 287 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / May 26, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, today announced an expansion of an existing... ► Artikel lesen | |
| 05.05. | Biovica International AB Announces Change in Executive Management | 348 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / May 5, 2026 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) - Biovica International AB ("Biovica") today announces that the company's Chief Financial... ► Artikel lesen | |
| 30.04. | Biovica International: New ESMO Data Highlights TKa Across Multiple Treatment Settings | 314 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / April 30, 2026 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) - Biovica today announces that three posters including TKa measurements will be presented... ► Artikel lesen | |
| 16.04. | Biovica International: Theis Kipling to Assume Role as CEO of Biovica on May 1, 2026 | 359 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / April 16, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica today announces that Theis Kipling will assume the role as Chief Executive Officer... ► Artikel lesen | |
| 07.04. | Biovica International: Theis Kipling New CEO for Biovica | 382 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / April 7, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The Biovica board has appointed Theis Kipling as the new Chief Executive Officer. He will... ► Artikel lesen | |
| 18.03. | Biovica International AB: Biovica International AB - Q3 Interim report Nov 2025-Jan2026 | 357 | GlobeNewswire (Europe) | 46% growth with strong momentum in the USA and for Pharma ServicesQ3 (Nov 2025-Jan 2026) (comparison figures are for the same period 2024/2025)Net sales amounted to SEK 3,294 (2,261), corresponding... ► Artikel lesen | |
| BIOVICA INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 09.03. | Nomination Committee for Biovica International AB for the 2026 Annual General Meeting | 377 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / March 9, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The Nomination Committee prior to the 2026 Annual General Meeting will consist of four members... ► Artikel lesen | |
| 05.03. | Biovica International: Biovica Announces Planned CEO Succession; Anders Rylander to Step Down During 2026 | 390 | ACCESS Newswire | UPPSALA, SWEDEN / ACCESS Newswire / March 5, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The Board of Directors of Biovica International AB today announces that Chief Executive... ► Artikel lesen | |
| 12.02. | Biovica International: Newly Published Data Reinforce Robust Prognostic Associations for DiviTum TKa in Metastatic Breast Cancer | 312 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / February 12, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, today announces that results from... ► Artikel lesen | |
| 27.01. | Biovica International: Strong DiviTum TKa Results Published in JCO Precision Oncology | 318 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / January 27, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II), a leader in blood-based cancer monitoring, today announced that DiviTum TKa data from... ► Artikel lesen | |
| 18.12.25 | Biovica International AB - Q2 Interim report Aug - Oct 2025 | 430 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / December 18, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Positioned for growth in Pharma Services and in the USAQ2 (August- October 2025) (comparison... ► Artikel lesen | |
| 15.12.25 | Biovica International: Biovica Signs Client Bill Agreement with Leading U.S. NCI-Designated Cancer Center | 375 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / December 15, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, today announced that the company... ► Artikel lesen | |
| 26.11.25 | Biovica International: Two New Studies with DiviTum TKa Presented at SABCS 2025 | 440 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / November 26, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, today announces the presentation... ► Artikel lesen | |
| 23.09.25 | Announcement from the Annual General Meeting in Biovica International AB | 463 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / September 23, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The annual general meeting of Biovica International AB ("Biovica" or the "Company")... ► Artikel lesen | |
| 11.09.25 | Biovica International: Biovica Q1 Interim Report May 2025 - July 2025 | 453 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / September 11, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Partnership agreement with Tempus and continued organic growth in the USASEK 000sQ1... ► Artikel lesen | |
| 22.08.25 | Notice Of Annual General Meeting in Biovica International AB | 395 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / August 22, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The shareholders of Biovica International AB, reg. no. 556774-6150 (the "Company"), are... ► Artikel lesen | |
| 13.08.25 | Biovica International: Biovica Carries Out a Directed Share Issue of Approximately MSEK 42.2 | 557 | ACCESS Newswire | NOT TO BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA... ► Artikel lesen | |
| 05.08.25 | Biovica International: Biovica announces outcome of rights issue | 548 | ACCESS Newswire | NOT TO BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA... ► Artikel lesen | |
| 25.07.25 | Biovica International: Biovica Launches DiviTum TKa for Use in Early Breast Cancer | 476 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / July 25, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, today announces the launch of DiviTum... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,55 | -3,41 % | Vorsicht bei BioNTech! Novo Nordisk gibt Gas! Kaufchance bei Vidac Pharma Aktie! | Kaufstimmung bei Novo Nordisk. Die Aktie des dänischen Pharmagiganten scheint den seit Sommer 2024 begonnenen Abwärtstrend zu verlassen. Anleger reagieren auf positive Meldungen. Bei Vidac Pharma ist... ► Artikel lesen | |
| EVOTEC | 5,125 | -3,39 % | Evotec holt KI-Manager von AstraZeneca | Evotec verstärkt den Bereich Künstliche Intelligenz und computergestützte Forschung mit einem erfahrenen Branchenmanager. Rui Wang übernimmt die neu geschaffene Position des Head of Global In Silico... ► Artikel lesen | |
| BB BIOTECH | 45,900 | -2,55 % | BB Biotech: "Wachstumsstarke Mid- und Small Caps bilden das Rückgrat unseres Portfolios": Mehr Einzelwerte und ... | ||
| MEDIGENE | 0,027 | -6,21 % | PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt | DJ PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Sonstiges... ► Artikel lesen | |
| MODERNA | 38,365 | -3,13 % | Moderna, Inc.: Moderna to Present at Upcoming Conference in June 2026 | CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:Goldman Sachs 47th Annual Global Healthcare... ► Artikel lesen | |
| PAION | 0,065 | -21,21 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 2,352 | -6,44 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
28.05.2026 / 17:08 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
| EPIGENOMICS | 0,870 | 0,00 % | PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung | DJ PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Hauptversammlung gemäß -- 121 Abs. 4a AktG
Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Heidelberg... ► Artikel lesen | |
| NOVAVAX | 8,670 | -4,09 % | Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It | ||
| STRYKER | 253,90 | -1,40 % | Stryker bringt das Pangea-Plattensystem auf den Markt und schließt den ersten Eingriff in Europa ab | Stryker (NYSE:SYK), ein weltweit führendes Unternehmen im Bereich Medizintechnik, gab heute die Markteinführung seines Pangea-Plattensystems in Europa bekannt, einer Plattensystem-Plattform zur Behandlung... ► Artikel lesen | |
| BIOGEN | 162,04 | -1,96 % | UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus | Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus standard... ► Artikel lesen | |
| BIOFRONTERA | 2,510 | +2,87 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2026 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN QUARTALS 2026
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA BERICHTET ÜBER... ► Artikel lesen | |
| ILLUMINA | 138,86 | -1,75 % | Guggenheim raises Illumina stock price target on clinical market strength | ||
| CRISPR THERAPEUTICS | 46,495 | -0,19 % | CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking | ||
| NANOREPRO | 1,820 | -1,62 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
26.05.2026 / 08:45... ► Artikel lesen |